Sun Mei, Shan Jian-Zhen, Zhang Guo-Ping, Ying Hua-Zhong
Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou 310009, China.
Zhongguo Zhong Yao Za Zhi. 2007 Apr;32(7):616-9.
To observe the effects of Taizhi'an capsule in treatment of hyperlipidemic fatty liver.
The model rats were induced by feeding high caloric diet for 8 weeks, then fifty rats were randomly divided into five groups, and each group had ten rats, the Taizhi'an groups (high dose 1 000 mg x kg(-1), middle dose 500 mg x kg(-1), low dose 250 mg x kg(-1)), the Yishanfu group and the model group. Liver index (liver weight/body weight), liver function, blood lipid, liver lipid, the content of MDA and SOD in liver were assayed after therapy, and observe Pathologic changes in rats liver.
Liver index, blood lipid, liver lipid, liver function increased significantly (P < 0.001) in model rats, and the content of SOD in liver decreased significantly (P < 0.05), Liver histology expressed mild to moderate fat denaturation; After being treated with high and middle dose of Taizhi'an capsule for six weeks, blood lipid, liver function decreased significantly (P < 0.001), and liver lipid decreased significantly (P < 0.001, P <0.05), the content of SOD in liver increased significantly (P < 0.05), meanwhile liver histology was closed to normal.
Taizhian capsule is effective in the treatment of hyperlipidemic induced fatty liver.
观察泰脂安胶囊治疗高脂血症性脂肪肝的疗效。
采用高热量饲料喂养8周诱导大鼠建立模型，将50只大鼠随机分为5组，每组10只，即泰脂安组（高剂量1000mg·kg-1、中剂量500mg·kg-1、低剂量250mg·kg-1）、易善复组和模型组。治疗后测定肝指数（肝重/体重）、肝功能、血脂、肝脂、肝组织中丙二醛（MDA）含量及超氧化物歧化酶（SOD）活性，并观察大鼠肝脏病理变化。
模型大鼠肝指数、血脂、肝脂、肝功能显著升高（P<0.001），肝组织SOD活性显著降低（P<0.05），肝脏组织学表现为轻至中度脂肪变性；高、中剂量泰脂安胶囊治疗6周后，血脂、肝功能显著降低（P<0.001），肝脂显著降低（P<0.001，P<0.05），肝组织SOD活性显著升高（P<0.05），同时肝脏组织学接近正常。
泰脂安胶囊对高脂血症性脂肪肝有治疗作用。
